M&A Commercial Due Diligence for $800M Pharma Acquisition

The target company had been in development for 7 years and was running low on cash. The Phase III oncology asset was 6 months from readout with promising Phase II data. The Phase II autoimmune asset had shown efficacy but faced a crowded competitive landscape with 5 drugs already approved in the same indication. The Phase I neurology asset was too early to value but had novel mechanism. The acquirer needed to determine whether the $800M asking price was justified by the risk-adjusted value of the 3 assets.

A top-15 pharma company was evaluating a $800M acquisition of a late-stage biotech with 3 assets: one Phase III oncology drug, one Phase II autoimmune drug, and one Phase I neurology drug. The BD team had 4 weeks to deliver a commercial due diligence report to the investment committee. They needed risk-adjusted peak sales forecasts, competitive landscape analysis, pricing and reimbursement risk assessment, and a clear go/no-go recommendation with valuation support.

We conducted a rapid 4-week commercial due diligence engagement, analyzing market dynamics across 3 therapeutic areas, competitive intensity, pricing landscape, and peak sales potential. Our team used our pharma intelligence platform to benchmark each asset against comparable programs, assess competitive threats, and model risk-adjusted NPV. We delivered a comprehensive due diligence report with go/no-go recommendation and valuation range.

We recommended proceeding with the acquisition at a revised valuation of $680-720M (vs. $800M asking price). Our analysis showed that the Phase III oncology asset was the primary value driver ($520M risk-adjusted NPV), the Phase II autoimmune asset had moderate value ($140M) but faced significant competitive risk, and the Phase I neurology asset was a binary option ($50M risk-adjusted). We identified 7 specific risk factors that the investment committee should consider, including 2 material risks that could reduce the valuation by $150M.